Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.

Both the companies have agreed to develop new drugs for the treatment of central nervous system (CNS) diseases by focusing on orphan G protein-coupled receptors (GPCRs).

The collaboration will combine Boehringer’s discovery and clinical development expertise and Domain’s DTect-All and bioSens-All platforms to develop new GPCR-targeted drugs for neuropsychiatric disorders.

Based in Germany, Boehringer Ingelheim is a research-driven pharmaceutical company, while Domain Therapeutics is a Canadian biopharmaceutical company.

Belgian biopharmaceutical company UCB has agreed to invest £1bn ($1.27bn) to support a purpose-built facility and research and development activities aimed to accelerate early detection of deadly diseases.

The collaboration will use artificial intelligence (AI) to develop early disease detection technology and new treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The UK Government is supporting the project by providing £79m ($100.55m). The deal also includes a £50m ($63.6m) investment by Roche and a total of £80m ($101.8m) in funding from five cell and gene therapy companies.

Other companies involved in the partnership are IQVIA, Genomics England, Autolus, Oxford BioMedica, Cobra Biologics, Roslin CT, and Bellicum.

“The collaboration will use artificial intelligence (AI) to develop early disease detection technology and new treatments.”

Janssen Pharmaceutical affiliate Cilag International has entered a deal with argenx to collaborate on the development and global commercialisation of cancer immunotherapy cusatuzumab (ARGX-110).

argenx will receive an upfront payment of $300m from Janssen and be eligible to receive up to $1.3bn upon achieving development, regulatory and sales milestones.

Cusatuzumab is intended for the treatment of acute myeloid leukaemia (AML), high-risk myelodysplastic syndromes (MDS), next-generation CD70 antibodies, and other future indications.

The deal provides argenx with an option to participate in commercialisation efforts in the US and share royalties equally with its partner. argenx will, however, receive double-digit sales royalties outside the country.

Based in Belgium, Cilag International manufactures and distributes pharmaceutical products, while Dutch company argenx develops innovative antibody therapeutics for cancer and autoimmune diseases.